ARVN 250117 35.00C (ARVN250117C35000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ARVN250117C35000

Watchlist

0.75
0.000.00%

15min DelayTrading Jan 8 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | Arvinas: Vepdegestrant to Be Combined With Pfizer's Cdk4 Inhibitor Atirmociclib in a First-Line Phase 3 Trial Planned to Initiate in 2025
Reuters07:01 ET
Express News | Arvinas Inc - Topline Data From Veritac-2 Phase 3 Trial Expected in 1Q25
Reuters07:00 ET
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials With Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
GlobeNewswire07:00 ET
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Seeking AlphaDec 28, 2024 10:31 ET
Arvinas, Inc.'s (NASDAQ:ARVN) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Simply Wall StDec 28, 2024 08:04 ET
BofA Securities Maintains Arvinas(ARVN.US) With Buy Rating, Raises Target Price to $57
Moomoo NewsDec 19, 2024 05:36 ET · Ratings

Comments

Moomoo AI

Feb 26, 2024 13:36

Arvinas' high P/S ratio could be worrisome as revenue forecasts are not promising. The anticipated future revenues may not sustain the current positive sentiment. Without significant improvements, these prices may not be deemed reasonable.

Revenues Not Telling The Story For Arvinas, Inc. (NASDAQ:ARVN) After Shares Rise 28%

Moomoo AI

Feb 20, 2024 15:08

Sean Cassidy expressed confidence in the company's future and the promising clinical development and commercial opportunity for the PROTAC(R) protein degrader pipeline. The company's leadership acknowledged Cassidy's pivotal role in creating Arvinas' strong financial profile.

Press Release: Arvinas Announces Chief Financial Officer Transition

JP88

Dec 8, 2023 17:35

$Arvinas (ARVN.US)$ I hope everyone bought that sub 14 dip! This thing has been a beast.

Analysts Notebook

Jun 21, 2022 06:06

Columns Top upgrades and downgrades on 6/21: XOM, ADBE, UAA, BEKE and more

Upgrades
• $ABM Industries (ABM.US)$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp (AMT.US)$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight (CHD.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy (CHWY.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene (CNC.US)$ : Credit Suisse Upgrades to Outperform from...

Analysts Notebook

May 9, 2022 05:50

Columns Top upgrades and downgrades on 5/9

Upgrades
• $Cigna Group (CI.US)$ : Cowen Upgrades to Outperform from Market Perform - PT $329 (from $242)
• $DLocal (DLO.US)$ : New Street Research Upgrades to Buy from Neutral - PT $38
• $Goodyear Tire & Rubber (GT.US)$ : CFRA Upgrades to Buy from Hold - PT $20 (from $24)
• $Match group (MTCH.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $115 (from $140)
• $Prestige Consumer Healthcare (PBH.US)$ : Oppenheimer Upgrades to Outperform from Perform - P...